Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.56 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.53 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.49 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.49 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.49 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23001085 | 1.00 | FABP3 (0.56) | FABP3P2RY10GPR34ALDH1A1LPAR1 | |
| SCHEMBL20472539 | 1.00 | FABP3 (0.56) | FABP3P2RY10GPR34ALDH1A1LPAR1 | |
| SCHEMBL9027639 | 1.00 | FABP3 (0.56) | FABP3P2RY10GPR34ALDH1A1LPAR1 | |
| SCHEMBL52780 | 1.00 | FABP3 (0.56) | FABP3P2RY10GPR34ALDH1A1LPAR1 | |
| SCHEMBL16180754 | 0.96 | FABP3 (0.53) | FABP3P2RY10GPR34ALDH1A1LPAR1 | |
| SCHEMBL5190825 | 0.92 | FABP3 (0.62) | FABP3P2RY10GPR34 | |
| SCHEMBL5475892 | 0.92 | FABP3 (0.62) | FABP3P2RY10GPR34 | |
| SCHEMBL1643923 | 0.92 | FABP3 (0.62) | FABP3P2RY10GPR34 | |
| SCHEMBL23166803 | 0.89 | ALDH1A1 (0.53) | FABP3ALDH1A1LPAR1ENPP2LPAR4 | |
| SCHEMBL23091273 | 0.89 | ALDH1A1 (0.53) | FABP3ALDH1A1LPAR1ENPP2LPAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710927-A1 | OLEYLPHOSPHOCHOLINE IN THE TREATMENT OF LEISHMANIASIS | Oblita Therapeutics BVBA (BE) | 2026-03-18 | — | — | EP | claimed |
| US-12214081-B2 | Tablet dosage formulations of oleyl phosphocholine | OBLITA THERAPEUTICS BVBA (BE) | 2025-02-04 | — | — | US | claimed |
| US-20240307283-A1 | COMPOSITIONS AND METHODS FOR DECREASING PIGMENTATION | THE GENERAL HOSPITAL CORPORATION | 2024-09-19 | — | — | US | claimed |
| EP-3965739-B1 | TABLET DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE | OBLITA THERAPEUTICS BVBA (BE) | 2024-07-10 | — | — | EP | claimed |
| EP-4366837-A2 | COMPOSITSONS AND METHODS FOR DECREASING PIGMENTATION | The General Hospital Corporation (US) | 2024-05-15 | — | — | EP | claimed |
| WO-2023283554-A2 | COMPOSITSONS AND METHODS FOR DECREASING PIGMENTATION | THE GENERAL HOSPITAL CORPORATION (US) | 2023-01-12 | — | — | WO | claimed |
| US-20220183975-A1 | Tablet dosage formulations of oleyl phosphocholine | OBLITA THERAPEUTICS BVBA (BE) | 2022-06-16 | — | — | US | claimed |
| EP-3965739-A1 | TABLET DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE | Oblita Therapeutics BVBA (BE) | 2022-03-16 | — | — | EP | claimed |
| WO-2020208230-A1 | TABLET DOSAGE FORMULATIONS OF OLEYL PHOSPHOCHOLINE | OBLITA THERAPEUTICS BVBA (BE) | 2020-10-15 | — | — | WO | claimed |
| EP-2680857-B1 | OLEYL PHOSPHOCHOLINE FOR THE TREATMENT OF MYCOSIS | OBLITA THERAPEUTICS BVBA (BE) | 2019-04-24 | — | — | EP | claimed |
| CN-102245180-A | Compositions and methods for the treatment of altered alpha-synuclein function | PARKINSON S INST | 2011-11-16 | — | — | CN | claimed |
| EP-2361089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED -SYNUCLEIN FUNCTION | Parkinson's Institute (US) | 2011-08-31 | — | — | EP | claimed |
| EP-1827379-B1 | FORMULATIONS CONTAINING ALKYLPHOSPHOCHOLINES USING NOVEL NEGATIVE CHARGE CARRIERS | MAX PLANCK GESELLSCHAFT (DE) | 2010-12-15 | — | — | EP | claimed |
| US-20100254909-A1 | THERMOLABILE LIPOSOME WITH A CONTROLLED RELEASE TEMPERATURE | EIBL HANSJORG | 2010-10-07 | — | — | US | claimed |
| US-20100167286-A1 | Pluripotent cell lines and methods of use thereof | PARKINSON'S INSTITUTE (US) | 2010-07-01 | — | — | US | claimed |
| US-20100144676-A1 | OLEYL PHOSPHOCHOLINE | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2010-06-10 | — | — | US | claimed |
| WO-2010056413-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α-SYNUCLEIN FUNCTION | PARKINSON'S INSTITUTE (US) | 2010-05-20 | — | — | WO | claimed |
| WO-2010008486-A2 | PLURIPOTENT CELL LINES AND METHODS OF USE THEREOF | PARKINSONS INSTITUTE (US) | 2010-01-21 | — | — | WO | claimed |
| US-20060165767-A1 | Thermolabile liposome with a controlled release temperature | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2006-07-27 | — | — | US | claimed |
| US-5916884-A | CYTOTOXIC THERAPEUTIC COMPOUND; ANTITUMOR AGENT | MAX-PLANCK-GESELLSCHAFT ZUR FOEDERUNG DER WISSENSCHAFTEN (DE) | 1999-06-29 | — | — | US | claimed |